|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/46 | |
| A61K 38/43 | |||
| A61P 25/00 | |||
| A61K 38/48 | |||
| A61K 38/54 | |||
| A61K 38/47 | |||
| A61K 45/06 |
| (11) | Number of the document | 2701733 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12773720.3 |
| Date of filing the European patent application | 2012-04-20 | |
| (97) | Date of publication of the European application | 2014-03-05 |
| (45) | Date of publication and mention of the grant of the patent | 2019-04-03 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/034489 |
| Date | 2012-04-20 |
| (87) | Number | WO 2012/145651 |
| Date | 2012-10-26 |
| (30) | Number | Date | Country code |
| 201161477988 P | 2011-04-21 | US |
| (72) |
FALLON, Joan, M., US
HEIL, Matthew, US
SZIGETHY, James, F., US
FALLON, James, J., US
|
| (73) |
Curemark, LLC,
411 Theodore Fremd Avenue Suite 206 South, Rye, NY 10580,
US
|
| (54) | COMPOUNDS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| COMPOUNDS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS |